Representative statistics on population at risk of recurrence are not currently available because cancer registries do not collect data on recurrence.

In fact, the multitude of variables about the recurrence of cancer, such as: patient gender, race, patient age, background disease, diagnosis stage, nature of initial patient treatment (surgery, chemotherapy, radiation therapy, bone marrow transplantation, Biological drugs, immunotherapies), The types of drugs (general or targeted), precision of measuring Metastases (MRI, CT ..) and more, make it almost impossible to estimate representative sample of recurrence.

Therefore, general protocols (care plan) have been approved regarding the periodic follow-up examinations to be performed over a period.

Not all protocols are homogeneous and different medical institutes are conducting according to different protocols. The diversity is characterized by regions or therapeutic approaches.

The main problem with the diagnosis of cancer recurrence concerns the unbearable condition compelled on patients in the way that periodic test results give a zero-sum result.

That is, if the periodic test gave a negative result, the patient temporarily feels out of the danger zone and prays that this will be the result in the next test.

But if the test is positive - the patient has already entered the danger zone, as recurrence cancer is known to be more aggressive, almost resistant to conventional therapies and significantly reduces the overall chances of survival.

Is this unbearable situation inevitable in the lives of oncology patients? The answer is no!

At LIBI Diagnostics, we seek to develop the next-generation in bio-liquid technology that will diagnose cancerous presence in body fluids long before the results of those periodic tests.

Pre-metastatic diagnosis will allow better control of cancer cell division regulation and increase the chances of preventing future metastasis formation.

The primary purpose of the venture is to save human lives by reducing dependence on the zero-sum results of periodic examinations, diagnose cancer at the earliest developmental stage, prior to the formation of metastases.